Monica Crawford, MD
Rheumatology · Anniston, ALNPI 1225243603
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 37.4% of the total. Reporting peaked in 2019 at $1,123 and has fallen 76.2% since, to $267 in 2025. That places this record below the midpoint for rheumatology clinicians in AL, where the typical reported total is $8,965.
Across 355 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$816
- Amgen$661
- Pfizer$372
- Lilly USA, LLC$345
- Novartis$229
- plus $908 from 17 others
What the payments were for
- Food & beverage$5,312100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 126 | $1,988 |
| UCB, Inc. | 69 | $816 |
| Amgen(2 entities) | 44 | $661 |
| Pfizer | 27 | $372 |
| Lilly USA, LLC | 20 | $345 |
| Novartis | 13 | $229 |
| AstraZeneca(2 entities) | 11 | $179 |
| Mallinckrodt Enterprises LLC | 8 | $129 |
| GSK | 8 | $115 |
| Radius Health, Inc. | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $58 |
| Johnson & Johnson | 3 | $56 |
| Bristol Myers Squibb | 2 | $50 |
| Mallinckrodt Hospital Products Inc. | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Genentech USA, Inc. | 2 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Medexus Pharma, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$122
How this compares
$5,319 in reported general payments places this provider in the 40th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 70 | $461,776 |
| Humira(Cf) PenAdalimumab | 45 | $351,670 |
| Orencia ClickjectAbatacept | 61 | $339,662 |
| BenlystaBelimumab | 59 | $274,086 |
| Enbrel SureclickEtanercept | 18 | $171,759 |
| Xeljanz XrTofacitinib Citrate | 22 | $120,693 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $115,077 |
| Taltz AutoinjectorIxekizumab | 16 | $114,637 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $88,512 |
| Humira PenAdalimumab | 13 | $87,494 |
| OtrexupMethotrexate/Pf | 69 | $50,776 |
| TymlosAbaloparatide | 13 | $40,298 |
| ProliaDenosumab | 18 | $30,918 |
| Hydroxychloroquine Sulfate | 387 | $27,908 |
| Lidocaine | 103 | $21,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $1,988 | $476,05687 claims |
| GSKBenlysta | $115 | $274,08659 claims |
| UCB, Inc.Cimzia (2 Pack) | $816 | $88,51215 claims |
| Radius Health, Inc.Tymlos | $104 | $40,29813 claims |
| AmgenProlia | $661 | $30,91818 claims |
| Medexus Pharma, Inc.Rasuvo | $14 | $11,26821 claims |
| Hikma Pharmaceuticals USAMitigare | $14 | $4,16622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Anniston
- Vishala ChindaloreAnniston$25K
- Anthony TurkiewiczMountain Brk$2.2M
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Ray McLaughinTuscaloosa$332K
- Elizabeth PerkinsHoover$264K
- Peter SawayMountain Brk$166K
- Kenneth SaagBirmingham$143K
- Gino DivittorioMobile$139K
- Richard JonesNorthport$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.